Case report: A patient with EGFR L861Q positive adenosquamous lung carcinoma transforming into large cell neuroendocrine cancer after treatment with Almonertinib

被引：0
作者：
Cheng, Kele [1 ]
Zhu, Yong [1 ]
Sang, Ran [1 ]
Kuang, Zhongsheng [2 ]
Cao, Yang [2 ]
机构：
[1] Guangzhou Univ Chinese Med, Clin Sch 1, Guangzhou, Peoples R China
[2] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Oncol Ctr, Guangzhou, Peoples R China
来源：
FRONTIERS IN ONCOLOGY | 2025年 / 15卷
关键词：
Almonertinib; EGFR; mutation; neuroendocrine; large cell neuroendocrine carcinoma; LCNEC; adenosquamous carcinoma; MUTATIONS; PROGNOSIS; ORIGIN;
D O I：
10.3389/fonc.2025.1453066
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Almonertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, is selective for both epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and T790M resistance mutations. However, resistance to the third-generation EGFR-TKIs is still inevitable. Econdary EGFR mutations, and bypass pathway activation have been reported with Almonertinib therapy. This article presents a rare case report of a patient with EGFR L861Q positive adenosquamous lung carcinoma who transformed into large cell neuroendocrine carcinoma following treatment with Almonertinib. The patient exhibited disease progression 8 months after initiating Almonertinib treatment, and a blood genetic test revealed mutations in EGFR L861Q and EGFR L858R. A subsequent lung biopsy after progression confirmed the diagnosis of large cell neuroendocrine carcinoma, and subsequently treatment with cisplatin and etoposide was effective. Transformation into neuroendocrine carcinoma is one of the mechanisms behind resistance to Almonertinib in adenosquamous lung carcinoma. EGFR mutations may persist even after transformation into neuroendocrine carcinoma. For non-small cell lung cancer patients undergoing Almonertinib therapy, this case report emphasizes the importance of performing a timely pathological biopsy upon the emergence of resistance.
引用
收藏
页数：5
相关论文
共 31 条
  • [1] Who Classification of Tumours Thoracic Tumours: International Agency for Research on Cancer, (2021)
  • [2] Nicholson A.G., Tsao M.S., Beasley M.B., Borczuk A.C., Brambilla E., Cooper W.A., Et al., The 2021 who classification of lung tumors: impact of advances since 2015, J Thorac Oncol, 17, 3, (2022)
  • [3] Filosso P.L., Ruffini E., Asioli S., Giobbe R., Macri L., Bruna M.C., Et al., Adenosquamous lung carcinomas: A histologic subtype with poor prognosis, Lung Cancer, 74, 1, (2011)
  • [4] Watanabe Y., Tsuta K., Kusumoto M., Yoshida A., Suzuki K., Asamura H., Et al., Clinicopathologic features and computed tomographic findings of 52 surgically resected adenosquamous carcinomas of the lung, Ann Thorac Surg, 97, 1, (2014)
  • [5] Maeda H., Matsumura A., Kawabata T., Suito T., Kawashima O., Watanabe T., Et al., Adenosquamous carcinoma of the lung: surgical results as compared with squamous cell and adenocarcinoma cases, Eur J Cardiothorac Surg, 41, 2, (2012)
  • [6] Gawrychowski J., Brulinski K., Malinowski E., Papla B., Prognosis and survival after radical resection of primary adenosquamous lung carcinoma, Eur J Cardiothorac Surg, 27, 4, (2005)
  • [7] Lin G., Li C., Li P.S., Fang W.Z., Xu H.P., Gong Y.H., Et al., Genomic origin and Egfr-Tki treatments of pulmonary adenosquamous carcinoma, Ann Oncol, 31, 4, (2020)
  • [8] Shimizu J., Oda M., Hayashi Y., Nonomura A., Watanabe Y., A clinicopathologic study of resected cases of adenosquamous carcinoma of the lung, Chest, 109, 4, (1996)
  • [9] Tang S., Xue Y., Qin Z., Fang Z., Sun Y., Yuan C., Et al., Counteracting lineage-specific transcription factor network finely tunes lung adeno-to-squamous transdifferentiation through remodeling tumor immune microenvironment, Natl Sci Rev, 10, 4, (2023)
  • [10] Jia X.L., Chen G., Egfr and kras mutations in chinese patients with adenosquamous carcinoma of the lung, Lung Cancer, 74, 3, pp. 396-400, (2011)
1234